Atrial Septal Defect (ASD) is a congenital heart condition characterized by an abnormal opening between the upper two chambers of the heart, the atria. This opening, known as the septum, fails to close properly during fetal development, leading to a passage between the left and right atria. ASD can vary in size, and its impact on heart function depends on the size and location of the defect. In many cases, small ASDs may not cause noticeable symptoms and can go undetected for years. However, larger defects can potentially lead to complications, including an increased risk of developing heart-related issues such as arrhythmias, pulmonary hypertension, or stroke. Diagnosis often involves a combination of physical examinations, imaging tests, and echocardiograms. Treatment options range from monitoring for small, asymptomatic defects to more proactive interventions, such as surgical repair or catheter-based procedures, for larger or symptomatic cases. Advances in medical technology and treatment options have significantly improved the outlook for individuals with ASD, allowing for timely and effective management of this congenital heart condition. Regular follow-up care is essential to monitor heart health and address any potential complications, ensuring individuals with ASD can lead healthy and fulfilling lives
Title : Pharmacological advancement in pulmonary arterial hypertension treatment - Contribution of treprostinil dry-powder formulation
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Historical evolution from OPCAB to MIDCAB to mini OPCAB surgical technique and results
Federico Benetti, Benetti Foundation, Argentina
Title : Personalized and Precision Medicine (PPM) and PPN-guided cardiology practice as a unique model via translational applications and upgraded business modeling to secure human healthcare, wellness and biosafety
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibodies with functionality as a new generation of translational tools designed to monitor autoimmune myocarditis at clinical and subclinical stages
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation